Sir,
Anti-tumor necrosis factor-a (TNF-a) therapy has recently become established as a means of managing rheumatoid arthritis (RA). On the other hand, several adverse immunological effects, such as drug-induced vasculitis and systemic lupus erythematosus (SLE), have been identified, 1-3 but little is known about an association between golimumab and SLE, especially lupus nephritis (LN). [4] [5] [6] To the best of our knowledge, this is the first description of LN becoming accelerated during golimumab therapy.
A 62-year-old woman was diagnosed with RA in 1994. She was treated with methotrexate, which had been interrupted because of pancytopenia. A prior test had revealed that she was positive for anti-cyclic citrullinated peptide antibody. She presented with microscopic hematuria and proteinuria and underwent a first renal biopsy 12 years later during 2006. The findings showed diffuse mesangial proliferation with segmental deposits in capillary walls (Figure 1 (a) ). Subendothelial immune-complex electron-dense deposits were confirmed in the electron microscopy ( Figure 1 (b) ). Although neither anti-double-stranded DNA (anti-dsDNA) nor anti-Smith (anti-Sm) antibodies were detectable, the antinuclear antibody (ANA) titer was 1:640 with a homogeneous pattern. She also had alopecia and leukocytopenia but no splenomegaly. The pathological and clinical findings indicated a diagnosis of diffuse global proliferative LN with active lesions (International Society of Nephrology (ISN) classification, III-S (A)). Combined corticosteroid and cyclosporine therapy improved the LN activity with chronic renal damage. Cyclosporine therapy stabilized her renal function (serum creatinine, $1.5 mg/dl (133 mmol/l)) for the next three years. Golimumab (50 mg/month) was administered in September 2015 to control RA activity. One month later, she presented with general fatigue and appetite loss, and severe renal dysfunction with massive proteinuria. Laboratory findings comprised: white blood cells, 6200/ml; hemoglobin, 9.5 g/dl; platelets, 14.6 Â 10 4 /ml; serum creatinine, 7.24 mg/dl (658 mmol/l); ANA titer, 1:1280. Other antigen-specific antibodies including anti-dsDNA, anti-Sm, myeloperoxidase anti-neutrophil cytoplasmic, proteinase-3 anti-neutrophil cytoplasmic and anti-glomerular basement membrane antibodies were undetectable. Urinalysis revealed proteinuria (16.6 g/g of creatinine (g/gCr)) and microscopic hematuria (>100 red blood cells per high-power field). The findings of a second renal biopsy revealed diffuse global endocapillary proliferation with sclerotic glomeruli, and crescentic lesions (ISN classification, IV-G (A/C)) ( Figure 1 (c) and (d)). Immunofluorescence staining showed 2þ immunoglobulin (Ig)G deposits in the mesangial lesions and capillary loops (Figure 1 (e) ). Immunofluorescence was negative for IgA, IgM, kappa, lambda, C3, C1q and C4. The pathological and serological findings together with the clinical history of this patient suggested a diagnosis of LN that had become accelerated during golimumab therapy. Golimumab was immediately stopped and replaced with corticosteroid therapy. Her renal function progressed to end-stage renal disease and she has been undergoing maintenance hemodialysis.
Adverse immunological effects of anti-TNF-a agents have been documented 2,3 and glomerulonephritis has also been associated with anti-TNF-a agents. 1 Although glomerulonephritis in this patient might originally have been attributable to other causes, the elevated ANA levels and pathological findings supported an association between LN and golimumab.
Although details of the mechanisms through which anti-TNF-a agents induce autoimmune diseases remain unclear, the role of TNF-a in drug-induced SLE has been discussed. 7, 8 Therefore, golimumab might induce autoimmune diseases in a manner similar to that of other anti-TNF-a agents.
In conclusion, golimumab might induce LN in some patients and this is important to consider. 
